Carmeli, Y. Et Al. 2024. Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. The Lancet Infectious Diseases .

Carmeli, Y., Cisneros, J. M., Paul, M., Daikos, G. L., Wang, M., Torre-Cisneros, J., ... Singer, G.(2024). Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. The Lancet Infectious Diseases .

Carmeli, Yehuda Et Al. "Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial," The Lancet Infectious Diseases , 2024

Carmeli, Yehuda Et Al. "Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial." The Lancet Infectious Diseases , 2024

Carmeli, Y. Et Al. (2024) . "Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial." The Lancet Infectious Diseases .

@article{article, author={Yehuda Carmeli Et Al. }, title={Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial}, journal={The Lancet Infectious Diseases}, year=2024}